Europe Heparin Market to Expand at 5.2% CAGR from 2014 to 2022

Europe Heparin Market to Reach US$3.1 bn by 2022 due to High Incidence of Thrombosis Heparin is one of the most widely used injectable blood thinners. Its increasing application in the treatment and prevention of deep vein thrombosis, pulmonary embolism, unstable angina, and myocardial infarction has augmented the demand from the heparin market. In its report, titled “Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,� Transparency Market Research (TMR) provides insights into the factors influencing the Europe heparin market and its growth trajectory.

Based on an in-depth survey conducted in order to provide comprehensive data, the report pegs the overall value of the Europe heparin market at just over US$2 bn in 2013. Rising at a CAGR of 5.2%, the market is expected to reach US$3.1 bn by the end of 2022.

The Europe heparin market has been studied from two perspectives: by products and by countries. Based on products, the market has been segmented into three categories: unfractionated heparin, low-molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Unfractionated heparin is an anionic mixture of highly sulfated linear glucosamine-glycans having molecular weight ranging from 3,000 to 30,000 Da. Unfractionated heparin as anti-coagulants is majorly consumed in hospitals as prophylaxis or treatment of thrombotic disorders and dialysis. Occurrence of bleeding disorders and low

application areas are among the key restraints to the unfractionated heparin market in the Europe.

LMWHs are extracted by the enzymatic or chemical depolymerization of unfractionated heparin. Pertaining to high demand for LMWHs during various surgical procedures and treatment of venous thromboembolism (VTE) disease, its demand is anticipated to grow in forthcoming years. Ultra-low molecular weight heparin has molecular weights less than 4000 Da with enhanced anticoagulation activity as compared to low molecular weight heparin.

Majority of the research and development activities in Europe are intended to compare the activities of ULMWHs with LMWHs in cancer and neurological disorders which if receives market approval will have positive impact on the Europe heparin market. However high cost of ULMWHs would be a major drawback for the sales of product in near future.

Browse Full Research Report on Europe Heparin Market: http://www.transparencymarketresearch.com/europe-heparinmarket.html Geographically the market has been segmented into EU5 countries i.e.

United Kingdom, France, Italy, Spain, Germany and Rest of the Europe.

The German heparin market in 2013 accounted for the largest market share due to high demand for LMWHs and unfractionated heparin products. Moreover, number of surgical procedures such as cardiovascular surgeries, knee and hip replacement and Caesarean sections among others that are performed in Europe is relatively higher as compared to other European countries.

Followed by Germany is France where the heparin market is growing rapidly due to increasing incidence and prevalence of coagulation disorders over the last few years. Astonishingly, France being a

conservative market, the consumption of unfractionated heparin is high as compared to other EU5 countries. However, in forthcoming years the market will follow trends similar to Germany, especially with respect to LMWHs. According to the NHS, one in three patients who undergo hip or knee replacement without thrombophylaxis develops asymptomatic DVT, while one in 30 suffer from symptomatic VTE. Recently, chief medical officer (CMO), the Department of Health in the U.K. published an operating framework which requires risk assessment to be done for thrombosis in a minimum of 90% of patients admitted to hospitals. Such factors would propel the demand and growth of heparin in the U.K. Spain and Italy market have low contribution among the EU5 countries with respect to market revenues.

The United Nations (UN) projects that Spain would be the world’s oldest country by 2050. This is a major factor attributed to an increased risk of thrombosis, which would further propel demand for heparin in the region as aging is proportional to incidence of VTE. Major players in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. Recently in 2013, GSK’s divested and sold its heparin products Fraxiparine and Arixtra product to Aspen Pharma.

Browse Full Press Release on Europe Heparin Market: Press Release

About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis

provides forward-looking insight for thousands of decision makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com